Cyclooxygenase-2 and colorectal cancer chemoprevention: The β-catenin connection

Cancer Research

Volumn 66, Issue 23, 2006, Pages 11085-11088

  Castellone, Maria Domenica ^a,c   Teramoto, Hidemi ^b   Gutkind, J Silvio ^a  

^a NATIONAL INSTITUTE OF DENTAL AND CRANIOFACIAL RESEARCH   (United States)

^b Kojin Hospital   (Japan)

^c UNIVERSITY OF NAPLES FEDERICO II   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BETA CATENIN; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; GUANINE NUCLEOTIDE BINDING PROTEIN; NONSTEROID ANTIINFLAMMATORY AGENT; PROSTAGLANDIN E RECEPTOR; PROSTAGLANDIN E2; PROSTAGLANDIN EP2 RECEPTOR; UNCLASSIFIED DRUG;

CANCER GROWTH; CARDIOVASCULAR DISEASE; CHEMOPROPHYLAXIS; COLORECTAL CANCER; ENZYME ACTIVITY; GASTROINTESTINAL TOXICITY; HUMAN; INFLAMMATION; NONHUMAN; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION;

BETA CATENIN; COLORECTAL NEOPLASMS; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITORS; DINOPROSTONE; GTP-BINDING PROTEINS; HUMANS; MODELS, BIOLOGICAL; RECEPTORS, PROSTAGLANDIN E; SIGNAL TRANSDUCTION;

EID: 33845736892     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-06-2233     Document Type: Review

References (41)

1. Jemal A, Murray T, Ward E, et al. Cancer statistics, 2005. CA Cancer J Clin 2005;55:10-30.
2. Vogelstein B, Kinzler KW. Cancer genes and the pathways they control. Nat Med 2004;10:789-99.
3. Levy DB, Smith KJ, Beazer-Barclay Y, et al. Inactivation of both APC alleles in human and mouse tumors. Cancer Res 1994;54:5953-8.
4. Oshima M, Oshima H, Kitagawa K, et al. Loss of Ape heterozygosity and abnormal tissue building in nascent intestinal polyps in mice carrying a truncated Ape gene. Proc Natl Acad Sci U S A 1995;92:4482-6.
5. Tetsu O, McCormick F. β-catenin regulates expression of cyclin D1 in colon carcinoma cells. Nature 1999;398:422-6.
6. Mimori-Kiyosue Y, Tsukita S. Where is APC going? J Cell Biol 2001;154:1105-9.
7. Kikuchi A. Tumor formation by genetic mutations in the components of the Wnt signaling pathway. Cancer Sci 2003;94:225-9.
8. Balkwill F, Charles KA, Mantovani A. Smoldering and polarized inflammation in the initiation and promotion of malignant disease. Cancer Cell 2005;7:211-7.
9. Torrance CJ, Jackson PE, Montgomery E, et al. Combinatorial chemoprevention of intestinal neoplasia. Nat Med 2000;6:1024-8.
10. Brown JR, DuBois RN. COX-2: a molecular target for colorectal cancer prevention. J Clin Oncol 2005;23:2840-55.
11. Gupta RA, Dubois RN. Colorectal cancer prevention and treatment by inhibition of cyclooxygenase-2. Nat Rev Cancer 2001;1:11-21.
12. Sonoshita M, Takaku K, Sasaki N, et al. Acceleration of intestinal polyposis through prostaglandin receptor EP2 in Apc(Δ716) knockout mice. Nat Med 2001;7:1048-51.
13. Subbaramaiah K, Dannenberg AJ. Cyclooxygenase 2: a molecular target for cancer prevention and treatment. Trends Pharmacol Sci 2003;24:96-102.
14. Vane JR, Botting RM. Mechanism of action of nonsteroidal anti-inflammatory drugs. Am J Med 1998;104:2-8S; discussion 21-2S.
15. Eberhart CE, Coffey RJ, Radhika A, et al. Upregulation of cyclooxygenase 2 gene expression in human colorectal adenomas and adenocarcinomas. Gastroenterology 1994;107:1183-8.
16. Sheng H, Shao J, Kirkland SC, et al. Inhibition of human colon cancer cell growth by selective inhibition of cyclooxygenase-2. J Clin Invest 1997;99:2254-9.
17. Hull MA, Ko SC, Hawcroft G. Prostaglandin EP receptors: targets for treatment and prevention of colorectal cancer? Mol Cancer Ther 2004;3:1031-9.
18. 2 enhances intestinal adenoma growth via activation of the Ras-mitogen-activated protein kinase cascade. Cancer Res 2005;65:1822-9.
19. 2 administration. Carcinogenesis 2003;24:985-90.
20. Hansen-Petrik MB, McEntee MF, Jull B, et al. Prostaglandin E(2) protects intestinal tumors from nonsteroidal anti-inflammatory drug-induced regression in Apc(Min/+) mice. Cancer Res 2002;62:403-8.
21. 2 promotes angiogenesis in colorectal cancer. J Exp Med 2006;203:941-51.
22. 2. Oncology 2005;69 Suppl 1:28-32.
23. 2 transactivates EGF receptor: a novel mechanism for promoting colon cancer growth and gastrointestinal hypertrophy. Nat Med 2002;8:289-93.
24. 2 stimulates the growth of colon cancer cells via induction of amphiregulin. Cancer Res 2003;63:5218-23.
25. 2 regulates cell migration via the intracellular activation of the epidermal growth factor receptor. J Biol Chem 2003;278:35451-7.
26. 2 regulates the nuclear receptor NR4A2 in colorectal cancer. J Biol Chem 2006;281:2676-82.
27. Barish GD, Narkar VA, Evans RM. PPARδ: a dagger in the heart of the metabolic syndrome. J Clin Invest 2006;116:590-7.
28. Wang D, Wang H, Shi Q, et al. Prostaglandin E(2) promotes colorectal adenoma growth via transactivation of the nuclear peroxisome proliferator-activated receptor δ. Cancer Cell 2004;6:285-95.
29. Gupta RA, Wang D, Katkuri S, et al. Activation of nuclear hormone receptor peroxisome proliferator-activated receptor-δ accelerates intestinal adenoma growth. Nat Med 2004;10:245-7.
30. He TC, Sparks AB, Rago C, et al. Identification of c-MYC as a target of the APC pathway. Science 1998;281:1509-12.
31. Hino S, Tanji C, Nakayama KI, Kikuchi A. Phosphorylation of β-catenin by cyclic AMP-dependent protein kinase stabilizes β-catenin through inhibition of its ubiquitination. Mol Cell Biol 2005;25:9063-72.
32. 2 promotes colon cancer cell growth through a Gs-axin-β-catenin signaling axis. Science 2005;310:1504-10.
33. Mezhybovska M, Wikstrom K, Ohd JF, Sjolander A. The inflammatory mediator leukotriene D4 induces β-catenin signaling and its association with antiapoptotic Bcl-2 in intestinal epithelial cells. J Biol Chem 2006;281:6776-84.
34. Yang M, Zhong WW, Srivastava N, et al. G protein-coupled lysophosphatidic acid receptors stimulate proliferation of colon cancer cells through the β-catenin pathway. Proc Natl Acad Sci USA 2005;102:6027-32.
35. He TC, Chan TA, Vogelstein B, Kinzler KW. PPARδ is an APC-regulated target of nonsteroidal anti-inflammatory drugs. Cell 1999;99:335-45.
36. Taha AS, Hudson N, Hawkey CJ, et al. Famotidine for the prevention of gastric and duodenal ulcers caused by nonsteroidal antiinflammatory drugs. N Engl J Med 1996;334:1435-9.
37. Sporn MB, Liby KT. Cancer chemoprevention: scientific promise, clinical uncertainty. Nat Clin Pract Oncol 2005;2:518-25.
38. Mann JR, Backlund MG, DuBois RN. Mechanisms of disease: Inflammatory mediators and cancer prevention. Nat Clin Pract Oncol 2005;2:202-10.
39. Jakobsson PJ, Thoren S, Morgenstern R, Samuelsson B. Identification of human prostaglandin E synthase: a microsomal, glutathione-dependent, inducible enzyme, constituting a potential novel drug target. Proc Natl Acad Sci U S A 1999;96:7220-5.
40. 2 synthase-1 in breast cancer: a potential target for therapy. J Pathol 2006;208:356-63.
41. Klein S, McCormick F, Levitzki A. Killing time for cancer cells. Nat Rev Cancer 2005;5:573-80.